The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...
Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...
When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
IV edaravone-treated patient had longer disease progression milestone-free time for all 6 milestones compared with control. Treatment with intravenous (IV) edaravone was associated with fewer reported ...
Please provide your email address to receive an email when new articles are posted on . A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it ...
COLUMBUS, Ohio, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS ...
News Medical on MSN
First insights into familial ALS in Egypt reveal genetic variations and disease progression
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration ...
ALS is a progressive disease, meaning it worsens over time. Although there is no cure for ALS, medications and therapies are available to help manage the symptoms, slow the disease course, and prolong ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback